ÇѸ²´ëÇб³¼º½Éº´¿ø

¼­Àå¿ø ±³¼ö

  • Áø·á°ú ½ÅÀå³»°ú

Àü¹®Áø·áºÐ¾ß

½ÅÀåÁúȯ(´Ü¹é´¢, Ç÷´¢, ºÎÁ¾, ¿ä·Î°¨¿°), °íÇ÷¾Ð, Åëdz, ¸¸¼ºÄáÆϺ´, ´ç´¢½ÅÀåÇÕº´Áõ, ½ÅºÎÀüÁøÇà¾ïÁ¦(´ç´¢), ±Þ¼º½ÅºÎÀü, Åõ¼®Ä¡·á, ÁßȯÀÚÄ¡·á

ÀüÈ­ ¿¹¾à 1522-2500
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2024-11-11 ~ 2024-11-16)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ¿Ü·¡Áø·á
¿ÀÈÄ ¿Ü·¡Áø·á¿Ü·¡Áø·á
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ Á¹¾÷

¿ï»ê´ëÇб³ ÀϹݴëÇпø ÀÇÇÐ ¼®»ç

¿ï»ê´ëÇб³ ÀϹݴëÇпø ÀÇÇÐ ¹Ú»ç

°æ·Â

°æ·Â

¼­¿ï¾Æ»êº´¿ø ¼ö·Ã/³»°ú Àü°øÀÇ ¼ö·á

¼­¿ï¾Æ»êº´¿ø ½ÅÀå³»°ú ÀÓ»ó°­»ç/ºÐ°ú Àü¹®ÀÇ/Åõ¼® Àü¹®ÀÇ

ÇѸ²´ëÇб³ÇÑ°­¼º½Éº´¿ø ½ÅÀå³»°ú Á¶±³¼ö

ÇѸ²´ëÇб³ÇÑ°­¼º½Éº´¿ø ½ÅÀå³»°ú ºÎ±³¼ö

ÇѸ²´ëÇб³ÇÑ°­¼º½Éº´¿ø ½ÅÀå³»°ú ºÐ°úÀå

ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ½ÅÀå³»°ú ºÎ±³¼ö

ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ½ÅÀå³»°ú ±³¼ö

ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ½ÅÀå³»°ú ºÐ°úÀå

ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ÀûÁ¤Áø·áÁö¿ø½ÇÀå

¹Ì±¹ UC San Diego Medical Center ¿¬¼ö

ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»ó±³À° ¼ÒÀ§¿øȸ À§¿ø

ÁßȯÀÚÀÇÇÐ ¼¼ºÎÀü¹®ÀÇ

ÇÐȸȰµ¿

ÇÐȸȰµ¿

´ëÇÑ°íÇù¾ÐÇÐȸ Á¤È¸¿ø

2009 ~ 2011´ëÇÑ °íÇ÷¾ÐÇÐȸ º¸ÇèÀ§

2008 ~ 2009´ëÇÑ ½ÅÀåÇÐȸ Çù¿¬À§¿ø

¹Ì±¹½ÅÀåÇÐȸ(ASN) Á¤È¸¿ø

´ëÇÑÀüÇØÁúÇ÷¾ÐÇÐȸ Á¤È¸¿ø

´ëÇÑÁßȯÀÚÀÇÇÐȸ Á¤È¸¿ø

2005 ~ 2009´ëÇÑ ½ÅÀåÇÐȸ À繫À§¿ø

´ëÇѳ»°úÇÐȸ Á¤È¸¿ø

´ëÇѽÅÀåÇÐȸ Á¤È¸¿ø

³í¹®

´ëÇ¥ ³í¹® ¹× Àú¼­
1. Kim EJ, Choi MJ, Lee JH, Oh JE, Seo JW, Lee YK, Yoon, JW, Kim HJ, Noh JW, Koo JR. Extracellular Fluid/Intracellular Fluid Volume Ratio as a Novel Risk Indicator for All-Cause Mortality and Cardiovascular Disease in Hemodialysis Patients. PLoS One. 2017 Jan 18;12(1):e0170272.

2. Cho AJ, Kim SJ, Lee YK, Song YR, Oh J, Kim SG, Seo JW, Yoon, JW, Koo JR, Kim HJ, Noh JW. Effect of post-voiding urine volume on progression of renal function decline in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015 Jul;109(1):164-9.

3. Cho JA, Cho ST, Lee YK, Oh J, Kim SG, Seo JW, Yoon JW, Koo, JR, Kim HJ, Lee YS, Lee YG, Noh JW. The association between an abnormal post-voiding urine volume and a lower estimated glomerular filtration rate in patients with type 2 diabetes with no voiding symptoms. Korean J Intern Med. 2015 Jan;30(1):82-7.


4. Choi MJ, Yoon JW, Han SJ, Choi HH, Song YR, Kim SG, Oh JE, Lee YK, Seo JW, Kim HJ, Noh JW, Koo JR. The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures: a comparison with periprocedural hemofiltration. Int J Cardiol. 2014 Oct ; 176(3):941-5

5. Choi MJ, Seo JW, Yoon JW, Lee SK, Kim SJ, Lee YK, Noh JW, Koo JR. The malnutrition-inflammation-depression-arteriosclerosis complex is associated with an increased risk of cardiovascular disease and all-cause death in chronic hemodialysis patients. Nephron Clinical Practice. 2012 ; 122(1-2): 44-52

6. Koo JR, Yoon JW, Han SJ, Choi MJ, Park II, Lee YK, Kim SG, Oh JE, Seo JW, Kim HJ, Noh JW. Rapid analysis of plasma paraquat using sodium dithionite as a predictor of outcome in acute paraquat poisoning. Am J Med Sci. 2009 Nov ; 338(5):373-7

7. Kim Y, Jeong SJ, Lee HS, Kim EJ, Song YR, Kim SG, Oh JE, Lee YK, Seo JW, Yoon JW, Koo JR, Kim HJ, Noh JW, Park SH. Polymorphism in the promoter region of the klotho gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients. Korean J Intern Med. 2008 Dec ; 23(4):201-7

8. Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. Nephrol Dial Transplant. 2008 Oct ; 23(10):3240-6

9. Yang WS, Seo JW, Han NJ, Choi J, Lee KU, Ahn H, Lee SK, Park SK. High glucose-induced NF-kappaB activation occurs via tyrosine phosphorylation of IkappaBalpha in human glomerular endothelial cells: involvement of Syk tyrosine kinase. Am J Physiol Renal Physiol. 2008 May ; 294(5):F1065-75

10. Kim EJ, Kim HJ, Kim SG, Lee YS, Oh JE, Seo JW, Koo JR, Noh JW. Aloe-induced Henoch-Schonlein purpura. Nephrology (Carlton). 2007 Feb ; 12(1):109

11. Koo JR, Yoon JY, Joo MH, Lee HS, Oh JE, Kim SG, Seo JW, Lee YK, Kim HJ, Noh JW, Lee SK, Son BK. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci. 2005 Jan ; 329(1):1-5

12. Chang JW, Yang WS, Seo JW, Lee JS, Lee SK, Park SK. Continuous venovenous hemodiafiltration versus hemodialysis as renal replacement therapy in patients with acute renal failure in the intensive care unit. Scand J Urol Nephrol. 2004 ; 38(5):417-21


±¹³»ÇÐȸÁö ¹ßÇ¥³í¹®
1. ±èÀºÀÌ, ÀÌ¿µ±â, À̽¹Î, ÃÖ¸íÁø, ¼Û¿µ¸², ±è¼öÁø, ¹ÚÅÂÁø, ±è¼º±Õ, ¿ÀÁöÀº, ¼­Àå¿ø, À±Á¾¿ì, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. ÃâÇ÷ À§ÇèÀ» °¡Áø Ç÷¾×Åõ¼® ȯÀÚ¿¡¼­ Àú¿ë·® nafamostat mesilateÀÇ È¿°ú. ´ëÇѽÅÀåÇÐȸÁö 2011:30(1):61-66

2. Á¤Ã¢¼ö, ÀÌ¿µ±â, ÃÖÁ¾¼ö, À̽¹Î, ¼Û¿µ¸², ±è¼öÁø, ¹ÚÅÂÁø, ¿ÀÁöÀº, ¼­Àå¿ø, À±Á¾¿ì, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì, ÃÖ¼ºÈÆ. À¯Áö Ç÷¾×Åõ¼®À» ¹Þ´Â ¸»±â½ÅÁúȯ ȯÀÚÀÇ Æó°íÇ÷¾Ð. ´ëÇѽÅÀåÇÐȸÁö 2011:30(1):48-52

3. ±èÀºÀÌ, ÀÌ¿µ±â, À̽¹Î, ÃÖ¸íÁø, ¼Û¿µ¸², ±è¼öÁø, ¹ÚÅÂÁø, ±è¼º±Õ, ¿ÀÁöÀº, ¼­Àå¿ø, À±Á¾¿ì, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. ÃâÇ÷ À§ÇèÀ» °¡Áø Ç÷¾×Åõ¼® ȯÀÚ¿¡¼­ Àú¿ë·® nafamostat mesilateÀÇ È¿°ú. ´ëÇѽÅÀåÇÐȸÁö 2011:30(1):61-66

4. Ji Youn Kim, Seon Wook Park, Seung Hwa Lee, Yong Wook Kim, Min-Kyu Kim, Tae Jin Park, Jang Won Seo, Acute Purulent Staphylococcal Pericarditis with Cardiac Tamponade in a Hemodialysis Patient. ´ëÇѽÅÀåÇÐȸÁö 2010:29(1):162-166

5. ¿À¼÷ÀÇ, ÀÌ¿µ±â, ±èÁø°æ, À̵¿ÈÆ, ±è¼öÁø, ±è¼º±Õ, ¿ÀÁöÀº, ¼­Àå¿ø, À±Á¾¿ì, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. Àú¾ËºÎ¹ÎÇ÷ÁõÀ» º¸ÀÌ´Â Ç÷¾×Åõ¼® ȯÀÚ¿¡¼­ Ç÷û ¾ËºÎ¹Î¿¡ ´ëÇÑ ÄÉÅ佺Å׸±ÀÇ È¿°ú. ´ëÇѽÅÀåÇÐȸÁö 2010:29(1):82-88

6. ¹ÚÀÎÀÏ, ÃÖ¸íÁø, À±Á¾¿ì, ¿ÀÁöÀº, ¼­Àå¿ø, ±è¼º±Õ, ÀÌ¿µ±â, ±èÇüÁ÷, ³ëÁ¤¿ì, ±¸ÀÚ·æ. ÃâÇ÷ À§Ç輺ÀÌ Àִ ȯÀÚ¿¡¼­ Áö¼ÓÀû Á¤Á¤¸Æ ¿©°ú¼ú ½ÃÇà ½Ã »ý¸®½Ä¿°¼ö ÁÖ»ç¿Í nafamostat mesilateÀÇ Ç×ÀÀ°í È¿°úÀÇ ÀüÇâÀû ºñ±³ ¿¬±¸. ´ëÇѽÅÀåÇÐȸÁö 2009:28(3):205-210

7. À±¿µÈÆ, Á¶¼öÁø, ¼­Àå¿ø, º¯¼Ò¿µ, Ȳ¼ºÈñ, ±¸¼±¿µ, ±è¿ì°æ, ¹Î¾ç±â, ±Ç±âÇÑ. ´Ù³¶½Å ȯÀÚÀÇ ÇãÇ÷¼º ³úÁ¹Áß. ´ëÇѳúÁ¹ÁßÇÐȸÁö 2009:11(2):88-91

8. ¼Û¿µ¸², ±è¼º±Õ, ±èÀºÁ¤, ±è¼öÁø, ¹ÚÅÂÁø, ¼Û¿µ¼ö, ¿ÀÁöÀº, ÀÌ¿µ±â, ¼­Àå¿ø, À±Á¾¿ì, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. Åõ¼®À» ½ÃÀÛÇÏ´Â ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼­ °ü»óµ¿¸Æ ÁúȯÀÇ À¯º´·ü°ú ºñħ½ÀÀû ¼±º°°Ë»çÀÇ ÀÓ»óÀû À¯¿ë¼º. ´ëÇѽÅÀåÇÐȸÁö 2007:26(3):327-333

9. ÀÌ¿µ±â, ÀÌÇü¼®, ÁÖ¹ÎÇÏ, ±è¼º±Õ, ¼­Àå¿ø, ¿ÀÁöÀº, À±Á¾¿ì, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼­ Epoetin Alfa ÁÖ 1ȸ ¿ä¹ý°ú ÁÖ 2-3ȸ ÇÇÇÏÅõ¿©ÀÇ È¿°ú ºñ±³. ´ëÇѽÅÀåÇÐȸÁö2007:26(2):220-226

10. ÁÖ¹ÎÇÏ, ±¸ÀÚ·æ, À±Á¾¿ì, ÇÑ»óÁø, ¼Û¿µ¸², ±è¼öÁø, ¼Û¿µ¼ö, ±è¼º±Õ, ¿ÀÁöÀº, ÀÌ¿µ±â, ¼­Àå¿ø, ±èÇüÁ÷, ³ëÁ¤¿ì Ç÷¾×Åõ¼® ÁßÀÎ ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼­ ¿°Áõ°ú µ¿¸Æ°æÁ÷ ¹× ¿µ¾çÀå¾Ö¿ÍÀÇ »ó°ü°ü°è. ´ëÇѽÅÀåÇÐȸÁö2006:25(3):431-437

11. ÀÌÇظ®, ¼Û¿µ¸², ±è¼öÁø, ÁÖ¹ÎÇÏ, ±è¼º±Õ, ¿ÀÁöÀº, ¼­Àå¿ø, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì, ½Å»óÁØ, ÀÌ¿µ±â. Ç÷¾×Åõ¼®È¯ÀÚ¿¡¼­ Antibiotic lock protocolÀ» ÀÌ¿ëÇÑ µµ°ü °ü·Ã ±ÕÇ÷ÁõÀÇ Ä¡·á. ´ëÇѽÅÀåÇÐȸÁö 2006:25(3):431-437

12. ¼­Àå¿ø, ±è¿µ¼ø, ¼Õ±¤Ç¥, Çѽ¿ë, ±è¼º±Õ, ¿ÀÁöÀº, ÀÌ¿µ±â, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì, ±è±ÙÈ£. Åõ¼®È¯ÀÚ¿¡¼­ Ç÷û ÀÌ¿ÂÈ­ ¸¶±×³×½·ÀÇ ÃøÁ¤. ´ëÇѽÅÀåÇÐȸÁö2005:24(6):957-963

13. ½ÅÇö¿ø, ±èÁ¾¿±, ¹®½Â¸í, Àå¿ì¿µ, ¼­Àå¿ø. Carbamazepine¿¡ ÀÇÇÑ ±Þ¼º °£Áú¼º ½Å¿° 1¿¹. ´ëÇѽÅÀåÇÐȸÁö2005:24(3):470-474

14. Çѱǿì, ÀÌ¿µ±â, ÀÌÇظ®, Ȳ»óÀÍ, ±è¼º±Õ, ¿ÀÁöÀº, ¼­Àå¿ø, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. ½ÅÁõÈıºÀ¸·Î ³ªÅ¸³­ Àü½Å¼º È«¹Ý¼º ³¶Ã¢ ȯÀÚ¿¡¼­ È®ÀÎµÈ IgA ½Åº´Áõ 1¿¹. ´ëÇѽÅÀåÇÐȸÁö2005:24(2):326-331

15. ¼­Àå¿ø. Blood Pressure Measurement and ABP Monitoring. ´ëÇѽÅÀåÇÐȸÁö 2005:24(2):432-437

16. Ç¥¼ºÈñ, ¼­Àå¿ø, ¹ÚÁ¾ÇÏ, ±è±ÔÇ¥, ±è»óÇö, ÀåÀç¿ø, ¼º±Ôº¸, ¹Ú¼ö±æ. Ç÷¾×Åõ¼® ȯÀÚ¿¡¼­ ¹ß»ýÇÑ Ç㸮µ¿¸Æ ¹× ¾Æ·¡ ¹èº®µ¿¸ÆÀÇ Àڹ߼ºÃâÇ÷ 1¿¹. ´ëÇѽÅÀåÇÐȸÁö 2004:23(6):992-996

17. ÃÖÄ¡ÈÆ, Çѱǿì, ¹Ú±¤Çõ, Á¤Ã¶¼º, ±è¼º±Õ, ¿ÀÁöÀº, ¼­Àå¿ø, ÀÌ¿µ±â, ±¸ÀÚ·æ, ±èÇüÁ÷, ³ëÁ¤¿ì. CÇü °£¿°¿¡ µ¿¹ÝÇÑ ±Þ¼ÓÁøÇà »ç±¸Ã¼½Å¿° 1¿¹. ´ëÇѽÅÀåÇÐȸÁö 2004:23(6):1004-1008

18. À±ÀçÇÊ, ¼­Àå¿ø, ±è»óÇö, ¹Ú¼ö±æ. ¿ì¿¬È÷ ¹ß°ßµÈ ¹«Áõ»ó¼º ±âÁ¾¼º ¹æ±¤¿° 1¿¹: ±¹³» Áõ·Ê Á¾ÇÕ °íÂû. ´ëÇѽÅÀåÇÐȸÁö 2004:23(1):174-179

19. ±è±ÙÈ£, ±è¼Ò¿µ, Áֱǿí, ÀüÀº½Ç, ¼­Àå¿ø, ÀÌÀç¿í, ÇÑÁø¼®. ¿°ºÐ ¼·Ãë°¡ NSAID À¯¹ß ³ªÆ®·ý Àú·ù¿¡ ¹ÌÄ¡´Â ¿µÇâ: ¿øÀ§ ³×ÇÁ·Ð ³ªÆ®·ý ¿î¹ÝüÀÇ ¿ªÇÒ. ´ëÇѽÅÀåÇÐȸÁö 2003:22(5):522-531

20. ¼­Àå¿ø, ¹Î¿ø±â, ±èÀ¯¹Ì, ±Ç¼ø±æ, ±è»óÇö, ÀÌÁ¤ÀÍ, ÀåÀç¿ø, ¾ç¿ø¼®, ¹Ú¼ö±æ. Çö¼º ´Ü¹é´¢°¡ ÀÖ´Â ´ç´¢º´¼º ½ÅÁß È¯ÀÚ¿¡¼­ Ç÷û VCAM-1ÀÇ Áõ°¡. ´ëÇѽÅÀåÇÐȸÁö 2003:22(3):294-302

21. ±Ç¼ø±æ, ±è»óÇö, ÀÌÁ¤ÀÍ, ¼­Àå¿ø, ÀåÀç¿ø, ±è¼ø¹è, ¹ÚÁ¤½Ä. °ü»óµ¿¸Æ Áúȯ ¹× ¸Æ¾ÐÀÌ ½ÅºÎÀü ÁøÇà¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇѽÅÀåÇÐȸÁö 2003:22(3):313-320

22. ±èÀ¯¹Ì, ¼®ÇöÁ¤, ±è»óÇö, ±Ç¼ø±æ, ÀÌÁ¤ÀÍ, ¼­Àå¿ø, ¹Ú¼ö±æ. ±Þ¼º »ó±âµµ °¨¿° ÈÄ ¹ß»ýÇÑ Àü½Å¼º ¸ð¼¼Ç÷°ü ´©Ãâ ÁõÈıº 1¿¹. ´ëÇѽÅÀåÇÐȸÁö 2003:22(2):251-256

23. ÀÌÁ¤ÀÍ, ±Ç¼ø±æ, ±è»óÇö, ¼­Àå¿ø, ÀåÀç¿ø, ±è¼ø¹è, ÀÌ»ó±¸, ¹ÚÁ¤½Ä. Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼­ C¹ÝÀÀ´Ü¹é, ¸Æ¾Ð°ú °ü»óµ¿¸ÆÁúȯÀÇ °ü°è. ´ëÇѽÅÀåÇÐȸÁö 2003:22(1):102-108

24. ÀåÀç¿ø, ±èÀ¯¹Ì, ¼­Àå¿ø, Ãֱͼ÷, À¯¼öÁø, ÁöÇö¼÷, À¯Á¾¿ì, ¹Ú¼ö±æ. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ Ä¡·á Áß ÀÎÅÍÆä·Ð-¾ËÆÄ¿¡ ÀÇÇÑ ¿ëÇ÷¼º ¿äµ¶ ÁõÈıº 1¿¹. ´ëÇѽÅÀåÇÐȸÁö 2002:21(2):341-347

25. ¼­Àå¿ø, À¯Çý½Â, Á¤¿µ¿Á, À¯±³»ó, ¹Ú±¤Àç, ±è»ïÁ¤, ÀÌ»ó±¸. Ç÷¾×Åõ¼® ¹× Áö¼Ó¼º ¿Ü·¡ º¹¸· Åõ¼® ȯÀÚÀÇ Ç÷û Lipoprotein (a) ³óµµ : Apolipoprotein (a) Ç¥ÇöÇü¿¡ µû¸¥ ºñ±³. ´ëÇѽÅÀåÇÐȸÁö 1996:15(4):558-566

26. °­À翵, Á¤µÎ·Ã, ±è°æÁ¶, À¯±³»ó, ±è»óÁ¤, ¼­Àå¿ø, ¹Ú±¤Àç, ¹ÚÁ¤½Ä. r-HuEPO Åõ¿© ÈÄ º¹¸·Åõ¼® ȯÀÚÀÇ ¿µ¾çÁöÇ¥ÀÇ º¯È­¿¡ ´ëÇÑ ¿¬±¸. ´ëÇѽÅÀåÇÐȸÁö 1995:14(2):205-212